e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Treatment of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are patients who overuse short acting β2-agonists more likely to report high levels of asthma symptoms?
C. McCowan, G. Hoskins, M. Stewart, R. G. Neville (Dundee, United Kingdom)
Source:
Annual Congress 2003 - Treatment of asthma and COPD
Session:
Treatment of asthma and COPD
Session type:
Poster Discussion
Number:
2636
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. McCowan, G. Hoskins, M. Stewart, R. G. Neville (Dundee, United Kingdom). Are patients who overuse short acting β2-agonists more likely to report high levels of asthma symptoms?. Eur Respir J 2003; 22: Suppl. 45, 2636
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
"It‘s like living with a time bomb"– European patients‘ perspective on severe asthma symptoms
Source: Annual Congress 2005 - Severe asthma: perception and management
Year: 2005
Are patients who report persistent symptoms and days lost due to asthma more likely to be hospitalised in the subsequent year?
Source: Eur Respir J 2002; 20: Suppl. 38, 204s
Year: 2002
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Increasing proportion of children with asthma and atopic disease from high risk families. A consequence of parental recruitment?
Source: Eur Respir J 2006; 28: Suppl. 50, 837s
Year: 2006
Higher resource use and lower asthma-related QOL in patients with severe or difficult-to-treat asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 296s
Year: 2003
Are there sub groups of children with asthma where FeNO guided treatment is associated with reduced risk for asthma attacks?
Source: International Congress 2017 – Diagnostic tools in paediatric asthma
Year: 2017
Are a degree of asthma therapy related to asthma control impairment?
Source: Eur Respir J 2003; 22: Suppl. 45, 370s
Year: 2003
Treatment of severe childhood asthma: what’s the evidence?
Source: Annual Congress 2005 - Difficult asthma in children
Year: 2005
Enough is enough: misuse of NIV in the treatment of chronic patients with exacerbation of symptoms?
Source: Annual Congress 2013 –The dark side of the moon: when, why, and where I should not use NIV?
Year: 2013
Do anxiety and depression affect patients‘ perceived level of asthma control?
Source: Annual Congress 2008 - Markers and triggers of asthma
Year: 2008
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
Impact of physical activity level on symptomatology and functionality during an acute exacerbation in COPD patients.
Source: International Congress 2018 – Exploring the importance of daily physical activity in chronic respiratory disease
Year: 2018
How much is too much? The treatment of mild asthma
Source: Eur Respir J 2007; 30: 403-406
Year: 2007
Physiological impairments and exacerbation risk in COPD patients with less symptom and no frequent exacerbation history.
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021
Specific comorbidities and low adherence are independent risk factors for poorer asthma control and exacerbations in patients with difficult-to-control asthma
Source: International Congress 2019 – Long-term evaluation and control of airway diseases
Year: 2019
High use of SABAs is associated with higher exacerbation frequency
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
FeNO threshold used to select severe asthma patients for Dupilumab may be inappropriate>
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Different causes of COPD exacerbation: unable or not to use bronchodilator drugs and journey to high altitude
Source: Eur Respir J 2006; 28: Suppl. 50, 31s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept